Navidea biopharmaceuticals announces positive results of second interim analysis of ongoing phase 2b study in rheumatoid arthritis

Navidea biopharmaceuticals, inc. (nyse american: navb) (“navidea” or the “company”), a company focused on the development of precision immunodiagnosti

NAVB Ratings Summary

NAVB Quant Ranking